3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
12
Recruiting
11
Completed
6
Active not recruiting
3
Not yet recruiting
2
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
2
Tumor-Agnostic
1
Head & Neck
1
Conditions
Head and Neck Neoplasms
1
Carcinoma
1
Interventions
Cisplatin
21
pembrolizumab
12
Cetuximab
12
Radiotherapy
11
Carboplatin
10
Nivolumab
9
Radiotherapy, Intensity-Modulated
8
Fluorouracil
8
durvalumab
5
Standard of Care
5
epacadostat
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Drug Therapy
4
Cyclophosphamide
4
X-Rays
3
Radiosurgery
3
Radiation
3
Practice Guidelines as Topic
3
Panitumumab
3
Gene Expression Profiling
3
Docetaxel
3
Biopsy
3
fluoromisonidazole
2
fludarabine
2
cemiplimab
2
aldesleukin
2
Venlafaxine Hydrochloride
2
Thyroxine
2
Surveys and Questionnaires
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
nimotuzumab
×
Head & Neck
×
Clear all
NCT01345084
2025-03-28
NICAP
Eurofarma Laboratorios S.A.
Phase 3
Withdrawn